These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 10480233)
1. Removal of detergent and solvent from solvent-detergent-treated immunoglobulins. Trescec A; Simić M; Branović K; Gebauer B; Benko B J Chromatogr A; 1999 Aug; 852(1):87-91. PubMed ID: 10480233 [TBL] [Abstract][Full Text] [Related]
2. Ion-exchange chromatography separation of the detergent and the solvent from immunoglobulins after solvent-detergent treatment. Gebauer B; Simić M; Branović K; Trescec A; Benko B J Chromatogr A; 1999 Aug; 852(1):83-6. PubMed ID: 10480232 [TBL] [Abstract][Full Text] [Related]
3. Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR HyperD and C18 sorbents. Burnouf T; Sayed MA; Radosevich M; El-Ekiaby M Anal Biochem; 2009 Jun; 389(1):69-73. PubMed ID: 19303391 [TBL] [Abstract][Full Text] [Related]
4. Extraction of Triton X-100 and its determination in virus-inactivated human plasma by the solvent--detergent method. Strancar A; Raspor P; Schwinn H; Schütz R; Josic D J Chromatogr A; 1994 Jan; 658(2):475-81. PubMed ID: 8118553 [TBL] [Abstract][Full Text] [Related]
5. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Dichtelmüller HO; Biesert L; Fabbrizzi F; Gajardo R; Gröner A; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Pifat D; Osheroff W; Poelsler G Transfusion; 2009 Sep; 49(9):1931-43. PubMed ID: 19497061 [TBL] [Abstract][Full Text] [Related]
6. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602 [TBL] [Abstract][Full Text] [Related]
8. A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M Transfusion; 2006 Dec; 46(12):2100-8. PubMed ID: 17176321 [TBL] [Abstract][Full Text] [Related]
9. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products. Roberts P Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053 [TBL] [Abstract][Full Text] [Related]
10. Single-use technology for solvent/detergent virus inactivation of industrial plasma products. Hsieh YT; Mullin L; Greenhalgh P; Cunningham M; Goodrich E; Shea J; Youssef E; Burnouf T Transfusion; 2016 Jun; 56(6):1384-93. PubMed ID: 27125447 [TBL] [Abstract][Full Text] [Related]
11. Solvent/detergent-treated plasma: a tale of 30 years of experience. Liumbruno GM; Marano G; Grazzini G; Capuzzo E; Franchini M Expert Rev Hematol; 2015 Jun; 8(3):367-74. PubMed ID: 25695198 [TBL] [Abstract][Full Text] [Related]
12. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. El-Ekiaby M; Sayed MA; Caron C; Burnouf S; El-Sharkawy N; Goubran H; Radosevich M; Goudemand J; Blum D; de Melo L; Soulié V; Adam J; Burnouf T Transfus Med; 2010 Feb; 20(1):48-61. PubMed ID: 19778318 [TBL] [Abstract][Full Text] [Related]
13. Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M Biologicals; 2007 Oct; 35(4):349-53. PubMed ID: 17656111 [TBL] [Abstract][Full Text] [Related]
14. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Hellstern P; Sachse H; Schwinn H; Oberfrank K Vox Sang; 1992; 63(3):178-85. PubMed ID: 1448962 [TBL] [Abstract][Full Text] [Related]
15. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20. Roberts PL; Lloyd D; Marshall PJ Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782 [TBL] [Abstract][Full Text] [Related]
16. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII. Roberts PL Biologicals; 2008 Sep; 36(5):330-5. PubMed ID: 18674928 [TBL] [Abstract][Full Text] [Related]
18. Physico-chemical and biological properties of solvent/detergent treated immunoglobuin G preparations. Nesterova NV; Kurkina OV; Samoilenko VA; Skrynnyk MM Mikrobiol Z; 2009; 71(6):35-42. PubMed ID: 20455431 [TBL] [Abstract][Full Text] [Related]
19. Amberlite XAD-4 is a convenient tool for removing Triton X-100 and Sarkosyl from protein solutions. Scutteri L; Maltoni G; Hochkoeppler A Biotechniques; 2023 Jan; 74(1):45-50. PubMed ID: 36621959 [TBL] [Abstract][Full Text] [Related]
20. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Piët MP; Chin S; Prince AM; Brotman B; Cundell AM; Horowitz B Transfusion; 1990 Sep; 30(7):591-8. PubMed ID: 2402772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]